GNOM vs. ARKG
GNOM (Global X Genomics & Biotechnology ETF) and ARKG (ARK Genomic Revolution Multi-Sector ETF) are both Health & Biotech Equities funds. GNOM is passively managed, while ARKG is actively managed. Over the past 5 years, GNOM returned -10.46%/yr vs -15.45%/yr for ARKG. Their correlation of 0.89 suggests significant overlap in exposure. GNOM charges 0.50%/yr vs 0.75%/yr for ARKG.
Performance
GNOM vs. ARKG - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, GNOM achieves a 5.71% return, which is significantly lower than ARKG's 17.36% return.
GNOM
- 1D
- -0.98%
- 1M
- 5.80%
- YTD
- 5.71%
- 6M
- 7.83%
- 1Y
- 53.78%
- 3Y*
- -1.59%
- 5Y*
- -10.46%
- 10Y*
- —
ARKG
- 1D
- -2.16%
- 1M
- 12.21%
- YTD
- 17.36%
- 6M
- 14.32%
- 1Y
- 57.12%
- 3Y*
- 0.75%
- 5Y*
- -15.45%
- 10Y*
- 7.24%
GNOM vs. ARKG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
GNOM Global X Genomics & Biotechnology ETF | 5.71% | 18.65% | -15.99% | -8.63% | -36.27% | -15.93% | 51.52% | 1.56% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 17.36% | 23.04% | -28.24% | 16.22% | -53.90% | -33.92% | 180.40% | -0.09% |
Correlation
The correlation between GNOM and ARKG is 0.84, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.84 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.88 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.91 |
Correlation (All Time) Calculated using the full available price history since Apr 11, 2019 | 0.89 |
The correlation between GNOM and ARKG has been stable across timeframes, ranging from 0.84 to 0.91 - a consistent structural relationship.
GNOM vs. ARKG - Sectors Allocation Comparison
Sectors
GNOM
ARKG
Healthcare
Technology
-
Basic Materials
-
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
Industrials
-
-
Real Estate
-
-
Utilities
-
-
Healthcare
GNOM
ARKG
Technology
GNOM
ARKG
-
Basic Materials
GNOM
-
ARKG
-
Communication Services
GNOM
-
ARKG
-
Consumer Cyclical
GNOM
-
ARKG
-
Consumer Defensive
GNOM
-
ARKG
-
Energy
GNOM
-
ARKG
-
Financial Services
GNOM
-
ARKG
Industrials
GNOM
-
ARKG
-
Real Estate
GNOM
-
ARKG
-
Utilities
GNOM
-
ARKG
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
GNOM vs. ARKG — Risk / Return Rank
GNOM
ARKG
GNOM vs. ARKG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Global X Genomics & Biotechnology ETF (GNOM) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| GNOM | ARKG | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 2.04 | 1.40 | +0.65 |
Sortino ratioReturn per unit of downside risk | 2.89 | 2.08 | +0.81 |
Omega ratioGain probability vs. loss probability | 1.33 | 1.23 | +0.10 |
Calmar ratioReturn relative to maximum drawdown | 3.12 | 2.27 | +0.85 |
Martin ratioReturn relative to average drawdown | 9.01 | 5.46 | +3.55 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| GNOM | ARKG | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.04 | 1.40 | +0.65 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.31 | -0.34 | +0.03 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.18 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.09 | 0.13 | -0.23 |
Drawdowns
GNOM vs. ARKG - Drawdown Comparison
The maximum GNOM drawdown since its inception was -75.00%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for GNOM and ARKG.
Loading charts...
Drawdown Indicators
| GNOM | ARKG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -75.00% | -83.59% | +8.59% |
Max Drawdown (1Y)Largest decline over 1 year | -18.17% | -27.51% | +9.34% |
Max Drawdown (3Y)Largest decline over 3 years | -46.47% | -51.96% | +5.49% |
Max Drawdown (5Y)Largest decline over 5 years | -72.29% | -80.18% | +7.89% |
Max Drawdown (10Y)Largest decline over 10 years | — | -83.59% | — |
Current DrawdownCurrent decline from peak | -56.32% | -69.58% | +13.26% |
Average DrawdownAverage peak-to-trough decline | -40.54% | -35.86% | -4.68% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 6.30% | 11.46% | -5.16% |
Volatility
GNOM vs. ARKG - Volatility Comparison
The current volatility for Global X Genomics & Biotechnology ETF (GNOM) is 8.46%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 11.89%. This indicates that GNOM experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| GNOM | ARKG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.46% | 11.89% | -3.43% |
Volatility (6M)Calculated over the trailing 6-month period | 19.51% | 29.12% | -9.61% |
Volatility (1Y)Calculated over the trailing 1-year period | 26.50% | 41.24% | -14.74% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 33.56% | 45.62% | -12.06% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 34.17% | 41.13% | -6.96% |
GNOM vs. ARKG - Expense Ratio Comparison
GNOM has a 0.50% expense ratio, which is lower than ARKG's 0.75% expense ratio.
Dividends
GNOM vs. ARKG - Dividend Comparison
GNOM's dividend yield for the trailing twelve months is around 1.30%, while ARKG has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% |
GNOM Global X Genomics & Biotechnology ETF | 1.30% | 1.37% | 0.00% | 0.00% | 0.00% | 0.03% | 0.14% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
GNOM and ARKG have a correlation of 0.84, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ARKG has higher volatility (11.89%) compared to GNOM (8.46%). In terms of maximum drawdown, GNOM dropped -75.00% vs ARKG's -83.59%.
On 5-year performance, GNOM leads with -10.46% vs -15.45% for ARKG. On fees, GNOM is cheaper at 0.50% per year. On volatility, GNOM has been the lower-risk option at 8.46%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, GNOM has performed better with a -10.46% return vs -15.45%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
GNOM is cheaper with a 0.50% expense ratio, compared with 0.75% for ARKG.
GNOM has the higher dividend yield at 1.30%, compared with 0.00% for ARKG.
They also come from different issuers: Global X and ARK. Their fees differ too: 0.50% for GNOM and 0.75% for ARKG.
GNOM currently has the higher Sharpe Ratio (2.04 vs 1.40), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for GNOM and ARKG
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer